The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Lactobacilli-based drug compositions. Buy the report here.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well-established in the industry.

Innovation S-curve for the pharmaceutical industry

Lactobacilli-based drug compositions is a key innovation area in pharmaceutical

Lactobacillus is usually available as a probiotic. The commonly used commercial strains of lactobacillus are L. acidophilus, L. bulgaricus, L. casei, L. reuteri, and L. GG. It is generally used to treat and prevent diarrhoea such as rotaviral diarrhoea and traveller's diarrhoea. It is also used to treat other diseases such as irritable bowel syndrome, colic in infants, inflammatory bowel disease (IBD), oral thrush, urinary tract infections (UTIs), and skin infections such as eczema. It helps to break down food, absorb nutrients and fight foreign micro-organisms that cause diseases.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 200+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of lactobacilli-based drug compositions.

Key players in lactobacilli-based drug compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to lactobacilli-based drug compositions

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
Nestle 1242 Unlock company profile
Reckitt Benckiser Group 305 Unlock company profile
Novo Nordisk Foundation 288 Unlock company profile
Probiotical 258 Unlock company profile
Danone 256 Unlock company profile
Symrise 247 Unlock company profile
BioGaia 240 Unlock company profile
Chr. Hansen Holding 232 Unlock company profile
Morinaga Milk Industry 205 Unlock company profile
Meiji Holdings 199 Unlock company profile
DuPont de Nemours 192 Unlock company profile
CJ 139 Unlock company profile
Kraft Heinz 106 Unlock company profile
Archer Daniels Midland 99 Unlock company profile
4D Pharma 89 Unlock company profile
Asahi Group Holdings 81 Unlock company profile
Yakult Honsha 80 Unlock company profile
GenMont Biotech 79 Unlock company profile
Otsuka Holdings 79 Unlock company profile
Cell Biotech 74 Unlock company profile
Megmilk Snow Brand 71 Unlock company profile
SOFAR 70 Unlock company profile
Kerry Group 69 Unlock company profile
OptiBiotix Health 63 Unlock company profile
Royal DSM 61 Unlock company profile
Kirin Holdings 60 Unlock company profile
Evolve Biosystems 58 Unlock company profile
Soho Flordis International 58 Unlock company profile
Kotobuki Realty 58 Unlock company profile
NVP Healthcare 56 Unlock company profile
Qualigen Therapeutics 54 Unlock company profile
TCI 53 Unlock company profile
Inner Mongolia Yili Industrial Group 52 Unlock company profile
KoBioLabs 50 Unlock company profile
Procter & Gamble 49 Unlock company profile
Abbott Laboratories 48 Unlock company profile
Grape King Bio 47 Unlock company profile
MD Healthcare 45 Unlock company profile
L'Oreal 44 Unlock company profile
Advanced BioNutrition 40 Unlock company profile
Amorepacific Group 40 Unlock company profile
glac Biotech 39 Unlock company profile
Finch Therapeutics Group 36 Unlock company profile
Pendulum Therapeutics 35 Unlock company profile
BC Partners LLP 34 Unlock company profile
PharmaCyte Biotech 33 Unlock company profile
Spanish National Research Council 33 Unlock company profile
CKD Bio 31 Unlock company profile
Giuliani 31 Unlock company profile
Sapporo Holdings 31 Unlock company profile

Source: GlobalData Patent Analytics

Novo Nordisk Foundation is one of the leading patent filers for lactobacilli-based drug compositions. The company has several lactobacillus-based probiotic products, infant formulas, yogurts, and drinks. The company has also developed a strain that has a significant therapeutic effect on children hospitalised with bacterial diarrhoea that has also shown  to prevent nasal congestion in allergic rhinitis.

In terms of application diversity, 4D Pharma is the top company, followed by Spanish National Research Council and Novo Nordisk Foundation. In terms of geographic reach, Spanish National Research Council holds the top position, while 4D Pharma and Giuliani are in the second and third positions, respectively. To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.